Literature DB >> 7867006

Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck.

R Michalides1, N van Veelen, A Hart, B Loftus, E Wientjens, A Balm.   

Abstract

We evaluated the prognostic significance of overexpression of cyclin D1 in 47 patients with surgically resected squamous cell carcinomas of the head and neck. Overexpression of cyclin D1 was detected immunohistochemically using an affinity-purified polyclonal antibody directed against the carboxyl-terminal part of the cyclin D1 protein, applied to formalin-fixed, paraffin-embedded tissue sections. Overexpression of cyclin D1 was found in 30 of 47 head and neck squamous cell carcinoma (HNSCC) cases and was associated with a more rapid and frequent recurrence of disease (P = 0.027). There was a 5-year disease-free interval of 47% for HNSCC patients with a strong overexpression of cyclin D1 and of 80% for cyclin D1-negative HNSCC patients. Overexpression of cyclin D1 was also associated with a shortened overall survival of these patients (P = 0.0095), with a 5-year survival of 60% for the cyclin D1 strongly positive cases and of 83% for cyclin D1-negative cases. Overexpression of cyclin D1 appears to indicate poor prognosis in operable HNSCC.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7867006

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  75 in total

Review 1.  Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer.

Authors:  R J Michalides
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

Review 2.  Clinico-prognostic value of D-type cyclins and p27 in laryngeal cancer patients: a review.

Authors:  L Pignataro; G Sambataro; D Pagani; G Pruneri
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-04       Impact factor: 2.124

3.  Alterations of cell cycle regulators in localized synovial sarcoma: A multifactorial study with prognostic implications.

Authors:  C R Antonescu; D H Leung; M Dudas; M Ladanyi; M Brennan; J M Woodruff; C Cordon-Cardo
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 4.  Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma.

Authors:  Giovana R Thomas; Hari Nadiminti; Jacinto Regalado
Journal:  Int J Exp Pathol       Date:  2005-12       Impact factor: 1.925

5.  Influential factors on tumor recurrence in head and neck cancer patients.

Authors:  Christoph Matthias; Ulrich Harréus; Richard Strange
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-07-08       Impact factor: 2.503

6.  Amplification and overexpression of the cyclin D1 gene in head and neck squamous cell carcinoma.

Authors:  X Wang; Z P Pavelic; Y Q Li; L Wang; L Gleich; K Radack; J L Gluckman; P J Stambrook
Journal:  Clin Mol Pathol       Date:  1995-10

7.  Targeted inhibition of ATR or CHEK1 reverses radioresistance in oral squamous cell carcinoma cells with distal chromosome arm 11q loss.

Authors:  Madhav Sankunny; Rahul A Parikh; Dale W Lewis; William E Gooding; William S Saunders; Susanne M Gollin
Journal:  Genes Chromosomes Cancer       Date:  2013-11-25       Impact factor: 5.006

8.  High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells.

Authors:  Xin Huang; Susanne M Gollin; Siva Raja; Tony E Godfrey
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-09       Impact factor: 11.205

9.  Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma.

Authors:  S E Coupland; N Bechrakis; A Schüler; I Anagnostopoulos; M Hummel; N Bornfeld; H Stein
Journal:  Br J Ophthalmol       Date:  1998-08       Impact factor: 4.638

10.  Correlation of cyclin D1 and Rb gene expression with apoptosis in invasive breast cancer.

Authors:  J S de Jong; P J van Diest; R J Michalides; P van der Valk; C J Meijer; J P Baak
Journal:  Mol Pathol       Date:  1998-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.